RFX1

Across TCGA pan-cancer cohorts, RFX1 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of RFX1’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where RFX1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types RFX1 is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

HNSC, PDAC, and CCRCC are the cancer types where RFX1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RFX1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	II,III,IV	+0.087	.010	10	view →
PDAC	Female	II,III,IV	−0.335	<.001	8	view →
CCRCC	Male	All	+0.171	<.001	7	view →
LSCC	All	All	+0.068	.006	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

RFX1–HNSC

Open the HNSC breakdown →